Trial Profile
Efficacy and tolerability of nimotuzumab versus cisplatin (CDDP) concurrent with intensity modulated radiation therapy (IMRT) in patients with nasopharyngeal carcinoma (NPC).
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 21 Sep 2017
Price :
$35
*
At a glance
- Drugs Nimotuzumab (Primary) ; Cisplatin; Docetaxel; Fluorouracil
- Indications Nasopharyngeal cancer
- Focus Therapeutic Use
- 21 Sep 2017 New trial record